Jiangsu Simcere’s Edaravone, Borneol Sublingual Tablets for AIS Accepted by NMPA for Review
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that the National Medical Products Administration...
Shanghai Junshi Biosciences Gets FDA Approval for Phase III Study of Tifcemalimab in Small-Cell Lung Cancer
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877) has announced receiving approval from the US Food...
Worg Pharmaceuticals Secures RMB 1.1 Billion in Series C Financing for Global Expansion
Worg Pharmaceuticals, a Hangzhou-based developer of allergy drugs, has reportedly raised RMB 1.1 billion (USD...
AIM Vaccine Receives NMPA Approval for mRNA Vaccine Clinical Study Targeting COVID-19 Variants
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...
Sichuan Kelun-Biotech Biopharmaceutical Prices IPO at HKD 60.6 to 72.8 per Share
Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...
Shandong Buchang Pharmaceuticals’ BC001 Gets Clinical Trial Approval for Solid Tumors
Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a China-based pharmaceutical company, has announced receiving clinical...
Beijing Tiantan Biological Completes Phase I Study for Recombinant Coagulation Factor VIIa
China-based Beijing Tiantan Biological Products Co., Ltd (SHA: 600161) has announced the conclusion of a...
Shanghai’s SMPA Notification: Non-Winning Bids in VBP Round 8 Can Avoid “Higher Price” Label
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification concerning the 8th round of...
US FDA Issues Warning Letter to Chengdu KeCheng Fine Chemicals Over Communication Failures
The US FDA’s Center for Drug Evaluation (CDE) issued a warning letter to China-based Chengdu...
Grand Pharmaceutical Initiates Phase I Study for TLX250-CDx in Renal Mass Imaging
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...
Teva Pharmaceutical’s Copaxone Approved by NMPA for Multiple Sclerosis Treatment in China
The National Medical Products Administration (NMPA) website has indicated that Israel-based Teva Pharmaceutical Industries’ (NYSE:...
Fosun Pharmaceutical’s Sisram Opens Wellness Center in Chicago for Beauty and Health
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the establishment of...
Sanyou Biopharmaceuticals and Huadong Medicine Expand Partnership on Macromolecule Therapeutics
China-based Sanyou Biopharmaceuticals Co., Ltd has announced a licensing deal with compatriot firm Huadong Medicine...
Daewoong Pharmaceutical Files NDA in China for Potassium-Competitive Acid Blocker Fexuclu
South Korea-based Daewoong Pharmaceutical (KRX: 069620) has revealed that a new drug application (NDA) has...
Insilico Medicine’s AI-Discovered Drug INS018_055 Reaches Phase II Clinical Trial Milestone
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has announced that its lead pipeline candidate,...
Biomm Secures Late-Stage Biosimilar Candidate BAT2206 from Bio-Thera Solutions
Brazil-based biotechnology company Biomm (BVMF: BIOM3) has announced that it has in-licensed the late-stage biosimilar...
CDE Issues Guidelines for New Drug Benefit-Risk Assessment in Market Approval Filings
The Center for Drug Evaluation (CDE) has released a notice outlining the guidelines for “New...
CNIPA Launches Pilot for Priority Patent Review for Macau Applicants in Mainland China
The China National Intellectual Property Administration (CNIPA) has announced the commencement of a pilot program...
AstraZeneca’s Dapagliflozin and Metformin Combo Approved by China’s NMPA for Type 2 Diabetes
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received market approval...
Lion TCR Secures RMB 300 Million in Series B2 Financing to Advance Clinical Studies and Facility Construction
Singapore-based clinical-stage biotechnology company Lion TCR has announced the successful completion of its Series B2...